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Abstract
To develop and pretest an European Organization for the Research and Treat-
ment of Cancer Sexual Health Questionnaire (EORTC SHQ- 22) for the assess-
ment of physical, psychological, and social aspects of sexual health (SH) in male 
and female cancer patients and survivors. Questionnaire construction started 
with creating a list of relevant SH issues based on a comprehensive literature 
review. Issues were subsequently evaluated for relevance and prioritization by 
78 healthcare professionals (HCP) and 107 patients from 12 countries during 
in- depth interviews (phase 1). Extracted issues were operationalized into items 
(phase 2). Phase 3 focused on pretesting the preliminary questionnaire in a 
cross- cultural patient sample (n = 171) using debriefing interviews. Psychometric 
properties were preliminary determined using a principal component analysis 
and Cronbach’s alpha. We derived 53 relevant SH issues from the literature. 
Based on HCP and patient interviews, 22 of these 53 issues were selected and 
operationalized into items. Testing the preliminary 22- item short questionnaire 
resulted in a change of wording in five items and two communication- related 
items; no items were removed. Preliminary psychometric analysis revealed a 
two- factor solution and 11 single items; both scales showed good reliability 
indicated by a Cronbach’s alpha of 0.87 (sexual satisfaction) and 0.82 (sexual 
pain). Cross- cultural pretesting of the preliminary EORTC SH questionnaire 
has indicated excellent applicability, patient acceptance, and comprehensiveness 
as well as good psychometric properties. The final development phase, that is 
psychometric validation (phase four) including large- scale, cross- cultural field 
testing of the EORTC SHQ- 22, has commenced.
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Introduction
Cancer diagnosis and related treatments are well known 
to induce serious adverse effects regarding patients’ sexu-
ality [1–4]. Aggressive cancer treatment strategies can 
adversely impact on a patient’s physical functioning, for 
example reduced sexual desire, orgasmic problems, erectile 
dysfunction (males), and dyspareunia (females) [5] as 
well as body perception and emotional stability. In addi-
tion, cancer can trigger psychosexual and socio- behavioral 
problems including feelings of sexual unattractiveness, 
alterations to the patient’s sexual self- conception, or 
reproductive concerns [6–9]. Unlike many other conse-
quences of a cancer diagnosis, sexual impairments are 
not restricted to the treatment phase but highly persist 
in the survivorship period [10]. As a consequence, patients 
report notable reductions in quality of life (QOL) and 
a disruption of return to “normal” life after cancer treat-
ment [11, 12].
In order to comprehensively understand and adequately 
determine the impact of cancer on a patient’s SH, it is 
crucial to conceptualize SH as a multidimensional con-
struct, not only restricted to physical–functional aspects 
of sexuality but also comprising a psychosexual and 
socio- behavioral component [13, 14]. This is reflected 
by the WHO definition of SH as a state of physical, 
emotional, mental, and social well- being related to sexu-
ality [13].
Currently, a well- validated patient- reported outcome 
(PRO) measure applicable to female and male cancer 
patients that meets these requirements of a multidimen-
sional understanding of SH is lacking [15–18]. Available 
instruments are either group- specific, have not been vali-
dated for use in cancer care, have limited multicultural 
applicability, or do not cover the full range of bio- psycho- 
social sexual issues.
Thus, the EORTC Quality of Life Group (QLG) 
decided to develop a comprehensive EORTC SH ques-
tionnaire relevant to all patients with cancer. The EORTC 
QLG aims to develop reliable, high- quality PRO instru-
ments for measuring the multidimensional aspects of 
QOL in patients with cancer based on questionnaire 
development guidelines [19]. These PRO instruments 
including the EORTC QLQ- C30 and its modules can 
be used as a QOL outcome measure in clinical trials 
or for the purpose of monitoring in daily clinical prac-
tice [20].
The objective of our study was to develop an EORTC 
SH questionnaire applicable to male and female cancer 
patients at different treatment stages and in the survivor-
ship phase that reflects SH as a multidimensional construct. 
In this article, we present the results of the development 
phases 1–3 of the EORTC SHQ- 22.
Patients and Method
The study protocol was approved by the local ethical 
committees according to the national requirements.
Phase 1—Generation of QOL issues
Literature search
The literature was exhaustively searched using PubMed 
targeting on SH issues in patients/survivors with any cancer 
diagnosis. The search covered original, qualitative, English 
language research papers published in peer- reviewed jour-
nals from year 1993. We used an inclusive search strategy 
for sexual health and sexuality- related issues in patients 
and survivors with any cancer diagnosis. The following 
combinations of keywords were used: neoplasms [mesh] 
OR neoplas*[tw] OR tumor [tw] OR tumors [tw] OR 
tumou*[tw] OR cancer*[tw] OR carcinom*[tw] OR 
oncolog*[tw] AND Sexuality”[Mesh]) OR (sexual function) 
OR (sexual function[All Fields]) OR (sexual function[tiab]) 
OR (sexual dysfunction) OR (sexual dysfunction [All 
Fields]) or (sexual dysfunction [tiab]). Available SH self- 
report measures, derived from the Patient- Reported 
Outcome Quality of Life Instruments Database 
(PROQOLID), were reviewed [21]. We excluded quantita-
tive studies of sexual health issues indicated by total or 
subscale scores (no analysis by thematic content).
Interviews with patients and healthcare providers 
(HCP)
Extracted issues were evaluated in semistructured interviews 
with HCP. HCP were eligible if they had at least 6 months 
experience in cancer care, were experienced with SH in 
oncology, and were fluent in the language of the ques-
tionnaire provided. Patient eligibility criteria included the 
following: histologically confirmed diagnosis of cancer, any 
cancer site and stage, any time point on treatment/sur-
vivorship pathway, no cognitive impairments, mother 
tongue of the questionnaire provided, 18 years of age or 
above, and written informed consent. Both HCP and 
cancer patients/survivors rated the issue list for relevance 
on a 4- point Likert scale (0 = “not relevant at all” to 
3 = “very relevant”) and prioritized 50% of issues (dichoto-
mously) in order to determine their relative importance. 
Patients were invited to give feedback and suggest any 
other relevant issues not appearing on the list in order 
to determine breath of coverage.
Issue selection procedure—phase 1
Based on the results of the literature search and the evalu-
ation by patients and HCP, SH issues were defined relevant 
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and selected for further inclusion in the preliminary ques-
tionnaire according to the following predefined criteria 
in phase 1:
1. Mean score in HCP ≥ 2.
2. Priority rating HCP > 30%.
3. Mean score in patients ≥ 2.
4. Priority rating patients > 30%.
Issues that met 3 or 4 criteria were retained on the list; 
issues meeting 2 criteria or less were deleted. New issues 
generated by open feedback were included if mentioned 
by a third of the participants at least.
Phase 2—Construction of the item list
Retained issues were operationalized into items (4- point 
Likert scale), wording, and time frame (during the last 
4 weeks) compatible with the EORTC QLQ- C30 and its 
modules. The EORTC item library [22] was checked for 
relevant items; issues lacking an appropriate item in the 
item library were newly formulated. Item translation 
included a standardized forward–backward procedure [19].
Phase 3—Pretesting of the provisional 
questionnaire
In phase 3, the provisional questionnaire was pretested. 
Cancer patients and survivors representing the target 
population completed the preliminary EORTC SHQ- 22, 
followed by a structured interview with the researcher 
focusing on item wording, intrusiveness, comprehension, 
and comprehensiveness. Phase 3 patient eligibility criteria 
were idem to phase 1.
Issue selection procedure—phase 3
Criteria for item selection in phase 3 were as follows:
1. Mean score > 1.5,
2. Prevalence of scores 3 or 4 > 50%,
3. Range > 2 points,
4. Each of the four response categories of an item (not 
at all, a little, quite a bit, very much) was selected by 
at least 10% of the patients,
5. Less than 10% missing responses to the item and no 
significant concerns raised by participants. Items that 
were identified as troublesome or difficult to understand 
were considered for rephrasing or rewording.
Patient recruitment
In the collaborating centers, patient recruitment was 
conducted in accordance with requirements of the local 
ethical committees. Patients were approached by the 
collaborator or his or her research assistant within the 
clinical routine, invited for study participation, and 
provided written informed consent (in case of participa-
tion). Subsequently, patients completed the issue list 
and the semistructured interview (given previously) in 
phase 1; in phase 3, they completed the preliminary 
questionnaire and the debriefing interview. HCP were 
recruited directly by the collaborators in his or her 
research team and underwent the same assessment as 
patients did in phases 1 and 3.
Cross- cultural and cross- lingual questionnaire 
development
In order to guarantee a cross- cultural and cross- lingual 
applicability and validity of the questionnaire, the EORTC 
QoL group recommends a balanced distribution of coun-
tries/languages involved in the development process. To 
meet these requirements for the purpose of this study, 
we followed the EORTC QoL group questionnaire devel-
opment guidelines indicating that “the construction process 
should include at least three languages and countries, to 
include one representing each of the following groupings: 
(a) English- speaking countries; (b) Northern Europe; and 
(c) Southern Europe” (p. 4) [19] for phase 1; phase 3 
is supposed to be conducted in a wider range of countries 
and regions including at least six countries from English- 
speaking countries, northern, southern, and eastern Europe, 
and one non- European country. This project was, hence, 
conducted by collaborators from Austria, Croatia, 
Germany, Italy, the Netherlands, Spain, Taiwan, UK, 
Belgium, Greece, Poland, and France.
Statistical analysis
We analyzed results descriptively using means, standard 
deviations, and percentages in phase 1. In order to 
perform preliminary analysis of the scale structure of 
the questionnaire in phase 3, we used an explorative 
principal component analysis with the oblique rotation 
method (promax rotation) for factor extraction; the 
optimal number of factors was determined using eigen-
values >1. Conditional items (i.e., items for females 
and males only) were excluded from the analysis. Scale 
reliability (internal consistency) was determined by means 
of Cronbach’s alpha. SPSS 22 was used for the statistical 
data analysis [23].
Results
The entire process of issue generation and item selection 
across all phases is illustrated in Figure 1.
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Phase 1—Generation of QOL issues
Questionnaire structure
The questionnaire is designed and validated as a stand- 
alone measure allowing its use independent from the 
EORTC QLQ- C30 or together. This approach was agreed 
as the EORTC QLQ- C30 does not address SH as a sub-
domain of QOL relevant to all patients with cancer, thereby 
preventing a targeted supplementation of the questionnaire 
which is the development model for other disease- specific 
modules.
Literature review
Overall, 4518 PubMed records were screened by title and 
abstract, resulting in the exclusion of 3461 records. The 
remaining 989 manuscripts were screened; in- depth review 
of 65 articles was finally conducted. The literature review 
identified a total of 53 issues relating to the sexual response 
cycle and side effects impacting on sexual activity (physi-
cal domain), relationship and intimacy (social domain), 
global SH (psychological domain), and sex- specific issues 
as well as communication with HCP.
Interviews
A total of 107 patients with different cancer diagnoses 
and treatment stages from eight countries participated. 
About a fourth of patients were survivors, that is, had 
treatment more than 5 years previously, and were free 
from disease. Details on the clinical and sociodemographic 
patient data are shown in Tables 1 and 2. In total, an 
Figure 1. Process of issue generation and item selection across phase 1–3.
37 issues
22 issues
- Deletion of 3 issues implying 
behavioral norms or content-related 
redundancy;
- Deletion of 12 issues by EORTC 
group expert consensus 
Literature review: 53 
Interviews with healthcare professionals (n = 83) and 
patients (n = 107)
Fulfilled less than 3 of 4 selection 
criteria
Operationalization of 22 issues into items and construction of the preliminary EORTC SHQ-22
Translation into 9 languages (Croatian, Dutch, French, German, Greek, Italian, traditional Chinese, Polish and 
Spanish)
Pre-testing: patient interviews (n = 171)
The EORTC SHQ-22
- No deletion of items (all of them met 
selection criteria)
- Rewording of 7 items
- Change of item order
- Removal of definition of sexual health 
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interdisciplinary, cross- cultural sample of 83 HCP from 
13 countries (Australia, Austria, Belgium, Germany, 
Hungary, Denmark, Italy, Norway, the Netherlands, Spain, 
Sweden, United Kingdom and Taiwan) was included. 
HCP had different professional backgrounds (radiation 
oncology n = 20; medical oncology n = 5; gynecology 
n = 18; and general surgery physicians n = 10; specialist 
nurses n = 4; psycho- oncologists n = 16; and others 
n = 6) and were highly experienced with SH issues in 
oncology with more than half of the HCP having 10 
or more years of clinical experience. A total of 56% of 
the HCP were females.
Based on quantitative and qualitative interview data, 
the list was reduced to 22 issues as follows: A total of 
37 issues fulfilled at least three of four retention cri-
teria. Of these, another 15 issues were deleted since 
implying behavioral norms such as frequency data or 
content- related redundancy. Qualitative data did not 
generate additional issues. Table 3 presents the selection 
procedure of issues (i.e., physical, psychological, and 
social domain).
Phase 2—Construction of the item list: the 
provisional EORTC SHQ- 22
The 22 SH- related issues carried forward from phase 1 
were operationalized into items [19]. Following the model 
of other EORTC modules, we defined a time frame of 
4 weeks. A total of 5 items were retrieved from the EORTC 
item library [24]; 17 new items were developed.
The provisional questionnaire was subsequently trans-
lated into nine languages (Croatian, Dutch, French, 
German, Greek, Italian, Mandarin, Polish, and Spanish).
Phase 3—Pretesting of the provisional 
EORTC SHQ- 22
The provisional EORTC SHQ- 22 was pretested in a sample 
of 171 patients (12 countries). Almost 60% of participants 
Table 1. Sociodemographic and sexual health- related patient 
characteristics
Phase 1 (N = 107) Phase 3 (N = 171)
n1 % n %
Country
Austria 12 11.2% 11 6.4%
Croatia 15 14.0% 15 8.7%
Germany 21 19.6% 19 11.1%
Italy 10 9.3% 9 5.2%
Netherlands 15 14.0% 25 14.6%
Spain 10 9.3% 15 8.7%
Taiwan 10 9.3% 4 2.3%
UK 13 12.1% 13 7.6%
Belgium – – 15 8.7%
Greece – – 10 5.8%
Poland – – 17 9.9%
France 13 7.6%
Sex
Female 66 62% 101 59%
Male 41 38% 70 41%
Age
Mean (SD) 55 (11) years 55 (13) years
range 21–81 years 20–91 years
Sexual partner1
Yes 90 84% 143 84%
No 15 14% 26 15%
Education level
Compulsory school 
  education or less
24 22% 40 23%
Postcompulsory 
  school education
47 44% 72 42%
University level 30 28% 59 35%
1Current sexual partner.
Table 2. Clinical patient characteristics.
Phase 1 (N = 107) Phase 3 (N = 171)
n % n %
Cancer site1
Breast 43 40% 52 30.4%
Colorectal 17 16% 13 7.6%
Head and Neck 14 13% 15 8.7%
Prostate 8 7% 23 13.4%
Lung 5 5% 9 5.2%
Cervical 4 4% 8 4.6%
Ovarian 4 4% 12 7%
Endometrial/Cervical 2 2% 8 4.6%
Other (anal, kidney, 
  testicular, pancreas)
9 9% 23 13.4%
Other gynecological 
  cancers
– – 11 6.4%
Treatment status
Active treatment 72 67% 121 71%
No active treatment 34 32% 49 29%
Treatment2
Surgery 76 – 121 –
Radiation therapy 66 – 110 –
Chemotherapy 62 – 99 –
Antihormonal therapy 28 – 36 –
Others 5 – 18 –
Status of disease
No evidence of disease 53 50% 43 26%
Newly diagnosed 17 16% 90 54%
Recurrence 11 10% 17 10%
Progression 10 9% 18 11%
Survivor 23 22% 16 10%
Time of treatment completion
During the last 5 years 45 42% 73 43%
More than 5 years ago 9 8% 5 3%
Not completed yet 4 4% 5 3%
Missing 49 46% 88 51%
1Five patients had more than one cancer site. Only the current or main 
cancer sites are included in this table.
2Multiple answers were possible.
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Table 3. Decision on issue deletion after phase 1 based on relevance and priority ratings of patients (N = 107) and HCP (N = 83).
Issue
Relevance ratings (0–3 points) Priority for inclusion (yes–no) Criteria
HCP ratings  
Mean
Patient ratings  
Mean
HCP ratings  
N (%)
Patient ratings  
N (%) Fulfilled
Frequency of sexual activity 1.81 1.68 30 (36)3 53 (50)4 2 of 4
Reasons for being sexually inactive 2.201 1.57 39 (47)3 39 (36)4 3 of 45
Satisfaction with the frequency of sexual activity 2.261 2.052 48 (58)3 68 (64)4 4 of 4
Importance of having an active sexual life 2.281 2.102 40 (48)3 57 (53)4 4 of 4
Level of hesitation to initiate sexual activities 1.81 1.47 21 (25) 35 (33)4 1 of 4
Frequency of sexual desire 1.76 1.76 18 (22) 45 (42)4 1 of 4
Level of desire 1.79 1.70 18 (22) 39 (36)4 1 of 4
Distress caused by decreased libido 2.431 1.61 55 (66)3 51 (48)4 3 of 4
Satisfaction with frequency of sexual desire 2.021 1.91 30 (36)3 55 (51)4 3 of 45
Satisfaction with level of desire 2.161 1.74 27 (33)3 47 (44)4 3 of 4
Frequency of sexual arousal 1.70 1.56 15 (18) 40 (37)4 1 of 4
Level of sexual arousal 1.85 1.52 13 (16) 36 (34)4 1 of 4
Satisfaction with level of sexual arousal 2.381 1.86 50 (60)3 60 (56)4 3 of 4
Ability to achieve an orgasm 2.301 1.86 43 (52)3 64 (61)4 3 of 4
Difficulty to reach an orgasm 2.151 1.54 35 (42)3 47 (44)4 3 of 4
Satisfaction with the ability to orgasm 2.481 1.69 46 (55)3 53 (50)4 3 of 4
Satisfaction with the frequency of orgasm 2.101 1.58 31 (37)3 45 (42)4 3 of 4
Incontinence (urine/fecal) during foreplay or intercourse 2.391 0.87 55 (66)3 37 (35)4 3 of 4
Hair loss (indirectly) affecting sexual response 1.72 0.93 25 (30) 39 (36)4 2 of 4
Fatigue/lack of energy affecting sex life 2.451 1.75 56 (67)3 66 (62)4 3 of 4
Scarring/organ loss (indirectly) affecting sexual response/
satisfaction
2.421 1.45 51 (61)3 50 (47)4 3 of 4
Frequency of pain during/after sexual activity 2.541 1.39 62 (75)3 53 (50)4 3 of 45
Level of pain during/after sexual activity 2.571 1.26 57 (69)3 41 (38)4 3 of 4
Change in amount of affection expressed 2.141 1.71 30 (36)3 62 (58)4 3 of 4
The level of emotional intimacy 2.131 2.102 22 (27) 61 (57)4 3 of 4
Satisfaction with level of affection or intimacy 2.311 2.242 55 (66)3 64 (60)4 4 of 4
Fear that sex will be painful 2.461 1.06 59 (71)3 45 (42)4 3 of 4
Fear of injury during intercourse 2.081 0.87 31 (37)3 30 (28) 2 of 4
Fear harming the incision during intercourse 1.78 0.93 14 (17) 22 (21) 0 of 4
Satisfaction communication partner 2.431 2.352 54 (65)3 73 (68)4 4 of 4
Partner is afraid to touch. afraid to cause pain 2.211 1.54 37 (45)3 49 (46)4 3 of 4
Experience of emotional distance from spouse 2.351 1.40 46 (55)3 51 (48)4 3 of 4
Insecurity regarding ability to satisfy the partner 2.141 1.41 32 (39)3 46 (43)4 3 of 4
Partner response to changes in sexual functioning: 
accepting/rejecting
2.441 1.77 52 (63)3 59 (55)4 3 of 4
Level of comfort with one’s sexuality 2.201 1.92 36 (43)3 49 (46)4 3 of 4
Change in the presence of sexual fantasies 1.18 1.00 4 (5) 24 (22) 0 of 4
Level of sexual enjoyment 2.251 1.92 28 (34)3 48 (45)4 3 of 4
Sexual satisfaction 2.561 2.012 53 (64)3 62 (58)4 4 of 4
Reduced sexual enjoyment 1.90 1.55 17 (20) 41 (38)4 1 of 4
To what extent are sexual dysfunctions distressing 2.431 1.43 50 (60)3 48 (45)4 3 of 4
Need for care because of sexual difficulties 1.94 1.06 26 (31)3 33 (31)4 2 of 4
Communication about sexual issues with health 
professionals
2.421 1.33 59 (71)3 33 (31)4 3 of 4
Masturbation1 2.021 0.88 22 (27) 19 (18)
Male sexual health N = 41 N = 83 N = 83 N = 83
Dry orgasm 1.85 0.83 31 (37)3 11 (27) 1 of 4
Retrograde ejaculation 1.83 0.81 25 (30)3 6 (15) 1 of 4
Ability to get an erection 2.701 1.82 57 (69)3 29 (71)4 3 of 4
Ability to maintain an erection (firm enough for sex) 2.671 1.90 52 (63)3 32 (78)4 3 of 4
Satisfaction with ability to maintain erection or level of 
firmness
2.571 1.81 50 (60)3 21 (51)4 3 of 4
Level of confidence in getting an erection and keeping one 2.391 2.002 42 (51)3 28 (68)4 4 of 4
(Continued)
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were female; more than two- thirds (71%) of the patients 
were currently undergoing treatment and 10% were sur-
vivors; about 30% of patients were not sexually active; 
for details, see Tables 1 and 2.
Quantitative analysis revealed the following results: The 
criterion mean scores above 1.5 were met for all items 
but two (incontinence, pain during sexual activity). All 
items had a range >2 points. All responses in categories 
3 and 4 or 1 and 2 were >10% except for item 6 (incon-
tinence). Prevalence of scores 3 or 4 was >50% in 17 
items. The remaining five items, all relating to sexual 
activity, did not fulfill this criterion. The compliance rate 
was at least 90% for 16 items. The other items with a 
lower compliance rate related to sexual activity, to having 
a partner, and to communication with HCP.
In qualitative patient interviews, we recorded more than 
120 comments. Item intrusiveness was identified by only 
nine patients. A total of 30 patients (17.5%) considered 
some items to be of minor relevance or felt uncomfort-
able answering the items satisfaction with level of sexual 
desire, sexual activity, ability to reach an orgasm, and 
femininity/masculinity. Some items were rated difficult to 
answer by six patients, and upsetting or confusing by 
eleven patients. Overall, 23 (13.5%) patients raised addi-
tional issues, for example changed body image or changes 
of body- and self- image (n = 4), and masturbation (n = 3). 
A total of 22 patients considered being currently sexually 
active or having a partnership as an important a priory 
condition for questionnaire completion.
Interesting to note, the rate of refusal to participate in 
the study was exceptionally high in Poland (46%; patient 
age range: 60–67 years). Higher acceptance rates were 
found (75%) when patients between 42 and 47 years of 
age were interviewed in an anonymous setting.
Based on quantitative and qualitative results, we adapted 
or rephrased the items incontinence, pain during sexual 
activity, sexual activity, decreased libido, ability to reach 
an orgasm, satisfaction with level of intimacy, partner 
communication, and communication with HCP; for exam-
ple, item 14 “Have you been satisfied with your level of 
affection or intimacy?” was changed to “Have you been 
satisfied with your level of intimacy?” because patients 
challenged the use of two different subjects within one 
question. No items were deleted (see Table 4) or added. 
A distinct proportion of patients experienced the ques-
tionnaire to predominately refer to sexually active patients 
or patients in a romantic partnership. For others, items 
did not explicitly relate to their treatment. As a conse-
quence, item order was changed toward grouped sections 
comprising sexual activity, treatment- related questions, 
partner- related questions, general questions of SH, and 
sex- specific questions.
Psychometric properties
The exploratory factor analysis (principal component 
analysis) suggested a two- factor solution (sexual satisfac-
tion and sexual pain) and 11 single items accounting for 
65.4% of the variance. Both scales showed good internal 
consistency indicated by Cronbach’s alpha of 0.87 and 
0.82 (see Table 5) as well as good item- scale correlations 
of 0.7–0.8 for sexual satisfaction and 0.8–0.9 for sexual 
pain. The factor “sexual satisfaction” includes issues related 
to sexual activity, sexual enjoyment, sexual functioning, 
and intimacy, which will be further explored in phase 4.
Discussion
To the best of our knowledge, the EORTC SHQ- 22 is 
unique in terms of conceptualization. We followed the 
WHO definition of SH in order to construct an instru-
ment covering both, sexual functioning (including symp-
toms and treatment side effects) and a psychosexual 
component. This integrative approach has previously been 
Issue
Relevance ratings (0–3 points) Priority for inclusion (yes–no) Criteria
HCP ratings  
Mean
Patient ratings  
Mean
HCP ratings  
N (%)
Patient ratings  
N (%) Fulfilled
Change in masculinity/feeling less masculine 2.291 1.24 47 (57)3 21 (51)4 3 of 4
Female sexual health N = 66 N = 83 N = 83 N = 83
Insufficient/decreased lubrication 2.591 1.74 60 (72)3 43 (65)4 3 of 4
Frequency of spotting/bleeding after sexual intercourse 2.031 1.03 35 (42)3 24 (36)4 3 of 4
Change in femininity/feeling less feminine 2.531 1.50 63 (76)3 46 (69)4 3 of 4
Bold print indicates final issue inclusion; Results are based on descriptive statistics.
1HCP ratings: mean ≥ 2.
2Patient ratings: mean ≥ 2.
3HCP ratings ≥30%.
4Patient ratings ≥ 30%.
5Excluded by content redundancy or behavioral norms.
Table 3. (Continued)
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demonstrated to be of vital importance in cancer care 
[14]; this assumption was confirmed by our phase 1 results. 
Patients identified several issues beyond sexual functioning 
such as sexual satisfaction or partner communication as 
highly relevant. Of note, issues relating to frequency or 
norms of sexual activity were removed as experienced 
least relevant. The questionnaire is further designed to 
be used in survivors as sexual impairments persist into 
survivorship [25, 26]. Patient and HCP feedback under-
scored the relevance of SH problems in the survivorship 
phase and did not suggest a difference on- and off- 
treatment. Only incontinence and pain during intercourse 
seemed to be relevant only for subgroups of patients, 
which can be regarded as a questionnaire’s limitation. 
However, this approach has been followed by other EORTC 
questionnaires, for example the testicular cancer module, 
the EORTC QLQ- TC26 (Holzner et al., 2013). However, 
we have to acknowledge that the questionnaire does not 
address age- dependent issues.
The substantial sample size in phase 3 facilitated com-
prehensive, well- balanced patient feedback across countries 
and cancer sites. According to patient feedback, the items 
seem to cover the full range of SH issues, are well under-
stood, and not intrusive, except in Poland.
The previously reported patient reluctance to answer 
specific SH questions was reflected also in this study by 
an unsatisfactory compliance rate for some items [27]. 
Although this is an expected result as sexuality is well 
known to be an inherently sensitive subject, we have to 
acknowledge this limitation [28, 29]. Here, it was the 
items on sexual activity and communication that received 
lower compliance rates. A possible explanation is that for 
some patients, sexual activity is exclusively conceptualized 
as a partner- related activity (i.e., masturbation is not con-
sidered). Therefore, some patients may not have considered 
themselves to be sexually active unless they physically 
engaged in sexual activity with a partner, contributing to 
the 30% of respondents who classified themselves as not 
sexually active in this sample.
The preliminary, explorative psychometric analysis 
revealed two factors with good internal consistency above 
0.8 and numerous single items. In view of these empiric 
Table 4. Results of patient interviews—items after phase 3.
Item No. Item
Mean score (1 not at 
all – 4 very much)
Scoring 3 (quite a 
bit) or 4 (very much)
Missing 
data Decision1
1 Importance of sex life 2.8 69% 4 (2%) Revised
2 Distress by decreased libido2 2.0 71% 4 (2%) Revised
3 Satisfaction with sexual desire 2.5 52% 11 (6%) Unchanged
4 Sexual activity was enjoyable 2.7 60% 16 (9%) Unchanged
5 Satisfaction with the ability to reach an orgasm 2.5 49%3 17 (10%) Unchanged
6 Incontinence (urine/stool) 1.12 98% 18 (10%)4 Revised
7 Fatigue or a lack of energy affected sex life 2.4 54% 10 (6%) Unchanged
8 Cancer treatment affected sexual activity 2.7 42%3 12 (7%) Unchanged
9 Pain during/after sexual activity 1.52 87% 21 (12%)4 Unchanged
10 Worries that sex would be painful 1.9 75% 17 (10%) Unchanged
11 Satisfaction with communication with health 
professionals
2.4 53% 31 (18%)4 Revised
12 Satisfaction with communication (partner) 3.1 75% 19 (11%)4 Revised
13 Worries that their partner may cause them pain 
during sexual contact
1.7 82% 14 (8%) Unchanged
14 Satisfaction with affection or intimacy 2.8 64% 11 (6%) Revised
15 Insecure regarding the ability to satisfy their partner 2.1 64% 17 (10%) Unchanged
16 Sexual activity 2.1 34%3 4 (2%) Revised
17 Extent of their sexual enjoyment 2.3 47%3 11 (6%) Unchanged
18 Satisfaction with sex life 2.4 53% 10 (6%) Unchanged
19 Male patients only (N = 70): 
Confidence in an erection when having sex
2.3 37%3 7 (10%)4 Unchanged
20 Feeling less masculine 1.9 72% 3 (4%) Unchanged
21 Female patients only (N = 101): 
Dry vagina
2.3 60% 11 (11%)4 Unchanged
22 Feeling less feminine 2.3 60% 2 (2%) Unchanged
1Based on the criteria for item retention.
2Mean score ≤ 1.5
3Scoring 3 or 4 ≤ 50%.
4Compliance rate < 90%.
Results are based on descriptive statistics.
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results in phase 3, there seems to be an emphasis on 
sexual functioning at least in terms of the factor solution. 
Psychosexual and social issues are however covered by 
single items so that the integrative approach for the meas-
urement of sexual health is still reflected. Preliminary 
psychometric results need further confirmation in the final 
phase 4 validation study, which will incorporate confirma-
tory factor analysis. In addition, sample size restricted 
providing results for subgroup comparisons on sexual 
health outcome, for example age or cancer sites and cancer 
stages, which would have been interesting in terms of 
applicability. This is true in particular also for the groups 
of sexually active versus inactive patients. However, these 
analyses are provided in phase 4.
As indicated, we observed a good cross- cultural accept-
ance. One country- specific result was noted: In Poland, 
the rejection rate of patients approached for the study 
was distinctly higher compared to other countries. At this 
point, we can only hypothesize on related reasons as the 
protocol did not include the assessment of reasons for 
nonparticipation. From the qualitative debriefing interviews 
with patients and HCP, we gathered evidence of the impact 
of culture on the understanding of sexuality [30, 31]. We 
identified two Polish culture- specific factors, namely a 
high rate of very religious people and the upbringing of 
Polish (older) people making sexuality a taboo subject 
[32]. Sexuality as a taboo subject seems to have a long 
tradition in Poland [30].
Conclusions
The EORTC SHQ- 22 as a stand- alone, multidimensional 
QOL instrument to measure sexual health in patients with 
cancer is clinically applicable, covers relevant SH issues, 
and shows high acceptability across the heterogeneous 
target population. The final development phase, that is 
psychometric validation (phase 4) including large- scale, 
cross- cultural field testing of the EORTC SHQ- 22, is 
ongoing.
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